Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Aquestive Therapeutics, Inc.NASDAQ: AQST
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $4.42M fell 78.6% year over year, behind the +284.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 570.2% from the prior quarter. Over 3 fiscal years it compounded at +107.0% a year.
Context
- Financing cash flow amounted to 230.4% of revenue in FY2025, up 85.1 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -78.6% toward the trailing-twelve-month pace of +284.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 102.62M USD
- Year-over-year change
- +22.8%
- 4-year CAGR
- +35.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 102.62M | +22.8% |
| FY2024 | 2024-12-31 | 83.59M | +2003.5% |
| FY2023 | 2023-12-31 | 3.97M | -65.6% |
| FY2022 | 2022-12-31 | 11.56M | -61.6% |
| FY2021 | 2021-12-31 | 30.11M | — |
Financing Cash Flow vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's LTM Mar 2026 financing cash flow of $86.39M is the 3rd largest of the 10 companies compared; the peer median is $1.98M.
- Its year-over-year change of +284.0% is the 4th highest of 10, against a peer median of +59.4%.
- Financing cash flow amounts to 171.9% of revenue for AQST, versus a peer median of 11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.51B | +638.5% | — | 86.0% | |
| LTM Mar 2026 | $106.35M | +235.6% | — | 13.4% | |
| LTM Mar 2026 | $86.39M | +284.0% | +107.0% | 171.9% | |
| LTM Mar 2026 | $83.13M | +1.5% | +36.6% | 11.5% | |
| LTM Mar 2026 | $42.35M | -151.3% | +13.0% | 34.6% | |
| LTM Jun 2026 | $31.51M | +374.0% | — | 3.8% | |
| LTM Mar 2026 | $12.92M | -31.8% | -0.5% | 20.0% | |
| LTM Mar 2026 | $5.69M | +363.0% | -55.3% | 1.8% | |
| LTM Mar 2026 | $2.36M | +59.4% | — | 1.1% | |
| LTM Mar 2026 | $1.98M | -74.4% | +48.5% | 4.7% | |
| Peer median (excluding AQST) | $1.98M | +59.4% | +13.0% | 11.5% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.54M) | (54.41M) | (7.87M) | (44.14M) | (83.78M) |
| Depreciation & Amortization | 2.96M | 2.39M | 1.35M | 718K | 548K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.82M | 4.38M | 2.69M | 7.1M | 7.62M |
| Change in Working Capital | (1.73M) | 32.01M | (5.34M) | (9.96M) | 12.18M |
| Accounts Receivables | (5.35M) | 7.35M | (3.07M) | 1.09M | (10.37M) |
| Inventory | (1.58M) | (1.74M) | (989K) | 725K | (126K) |
| Accounts Payables | 1.23M | 1.63M | (1.02M) | 2.78M | 19.52M |
| Other Working Capital | 3.98M | 24.77M | (259K) | (14.56M) | 3.16M |
| Other Non-Cash Items | 29.51M | 5.85M | 2.8M | 10.52M | 11M |
| Operating Cash Flow | (32.98M) | (9.79M) | (6.38M) | (35.76M) | (52.43M) |
| Capital Expenditures | (913K) | (2.52M) | (995K) | (159K) | (562K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (913K) | (2.52M) | (995K) | (159K) | (562K) |
| Debt Repayment | 0 | (2.03M) | (20.39M) | (23K) | (37K) |
| Common Stock Issued | 29.78M | 13.59M | 8.91M | 83.76M | 103.46M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 329K | 1K | 15.45M | (142K) | (810K) |
| Financing Cash Flow | 30.11M | 11.56M | 3.97M | 83.59M | 102.62M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (3.78M) | (751K) | (3.4M) | 47.67M | 49.62M |
| Free Cash Flow | (33.89M) | (12.31M) | (7.38M) | (35.92M) | (52.99M) |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.